NAGIOS: RODERIC FUNCIONANDO

Oral microbiome and systemic antineoplastics in cancer treatment:a systematic review

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Oral microbiome and systemic antineoplastics in cancer treatment:a systematic review

dc.contributor.author	Rodríguez-Fuentes, Manuel Eros	es
dc.contributor.author	Pérez-Sayáns, Mario	es
dc.contributor.author	Chauca Bajaña, Luis	es
dc.contributor.author	Barbeito Castiñeiras, Gema	es
dc.contributor.author	Pérez del Molino Bernal, María Luisa	es
dc.contributor.author	López López, Rafael	es
dc.date.accessioned	2023-06-16T08:36:48Z
dc.date.available	2023-06-16T08:36:48Z
dc.date.issued	2022	es
dc.identifier.citation	Rodríguez-Fuentes, ME., Pérez-Sayáns, M., Chauca-Bajaña, LA., Barbeito-Castiñeiras, G., Molino-Bernal, ML., & López-López, R. (2022). Oral microbiome and systemic antineoplastics in cancer treatment: A systematic review. En Medicina Oral Patología Oral y Cirugia Bucal (pp. e248-e256). Medicina Oral, S.L. https://doi.org/10.4317/medoral.25121	es
dc.identifier.uri	https://hdl.handle.net/10550/88123
dc.description.abstract	Oral mucositis is one of the most common side effects in cancer patients receiving systemic antineoplastics. However, the underlying biological mechanisms leading to this condition are still unclear. For this reason, it has been hypothesised that systemic antineoplastics may cause an imbalance on the oral microbiota that subsequently triggers oral mucosa damage. A systematic review was performed following the PRISMA protocol and the PICO question established was: patients diagnosed with cancer, who are candidates for receiving systemic antineoplastics (P=Patients), that undergo oral microbiome determinations (I=Intervention), before and after systemic antineoplastics administration (C=Comparison), to analyse changes in the oral microbiome composition (O=Outcome). The bibliographic search was carried out in PubMed and other scientific repositories. Out of 166 obtained articles, only 5 met eligibility criteria. Acute myeloid leukaemia (AML) was the most frequent type of cancer (40 %) among the participants. Only one of the studies included a control group of healthy subjects. Heterogeneity in the protocols and approaches of the included studies hindered a detailed comparison of the outcomes. However, it was stated that a decrease in bacteria ? diversity is often associated with oral mucositis. On the other hand, fungal diversity was not associated with oral mucositis although ? diversity was lower at baseline on patients developing oral candidiasis. There is insufficient scientific evidence of oral microbiological changes in patients undergoing systemic antineoplastics. Further investigations ought to be carried out to identify microorganisms that might play a key role in the pathogenesis of oral mucosa damage in patients undergoing systemic antineoplastics.	es
dc.subject	surgery plastic	es
dc.subject	lipectomy	es
dc.subject	postoperative complications	es
dc.subject	hematoma	es
dc.title	Oral microbiome and systemic antineoplastics in cancer treatment:a systematic review	es
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO:CIENCIAS MÉDICAS	es
dc.identifier.doi	10.4317/medoral.25121	es
dc.type.hasVersion	VoR	es_ES
dc.identifier.url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054164/